These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23539239)

  • 1. Co-occurrence of amikacin-resistant and -susceptible Mycobacterium tuberculosis isolates in clinical samples from Beijing, China.
    Zhang X; Zhao B; Huang H; Zhu Y; Peng J; Dai G; Jiang G; Liu L; Zhao Y; Jin Q
    J Antimicrob Chemother; 2013 Jul; 68(7):1537-42. PubMed ID: 23539239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China.
    Du Q; Dai G; Long Q; Yu X; Dong L; Huang H; Xie J
    Diagn Microbiol Infect Dis; 2013 Oct; 77(2):138-42. PubMed ID: 23948547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China.
    Zhang Z; Liu M; Wang Y; Pang Y; Kam KM; Zhao Y
    Eur J Clin Microbiol Infect Dis; 2014 Nov; 33(11):1959-66. PubMed ID: 24906439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.
    Brossier F; Pham A; Bernard C; Aubry A; Jarlier V; Veziris N; Sougakoff W;
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
    Engström A; Perskvist N; Werngren J; Hoffner SE; Juréen P
    J Antimicrob Chemother; 2011 Jun; 66(6):1247-54. PubMed ID: 21427106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed Infections and Rifampin Heteroresistance among Mycobacterium tuberculosis Clinical Isolates.
    Zheng C; Li S; Luo Z; Pi R; Sun H; He Q; Tang K; Luo M; Li Y; Couvin D; Rastogi N; Sun Q
    J Clin Microbiol; 2015 Jul; 53(7):2138-47. PubMed ID: 25903578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables.
    Kambli P; Ajbani K; Nikam C; Sadani M; Shetty A; Udwadia Z; Georghiou SB; Rodwell TC; Catanzaro A; Rodrigues C
    Int J Mycobacteriol; 2016 Mar; 5(1):1-6. PubMed ID: 26927983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene.
    Jugheli L; Bzekalava N; de Rijk P; Fissette K; Portaels F; Rigouts L
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5064-8. PubMed ID: 19752274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan.
    Hofmann-Thiel S; van Ingen J; Feldmann K; Turaev L; Uzakova GT; Murmusaeva G; van Soolingen D; Hoffmann H
    Eur Respir J; 2009 Feb; 33(2):368-74. PubMed ID: 18829680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania.
    Kibiki GS; Mulder B; Dolmans WM; de Beer JL; Boeree M; Sam N; van Soolingen D; Sola C; van der Zanden AG
    BMC Microbiol; 2007 May; 7():51. PubMed ID: 17540031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance and IS6110-RFLP patterns of Mycobacterium tuberculosis in patients with recurrent tuberculosis in northern Thailand.
    Sukkasem S; Yanai H; Mahasirimongkol S; Yamada N; Rienthong D; Palittapongarnpim P; Khusmith S
    Microbiol Immunol; 2013 Jan; 57(1):21-9. PubMed ID: 23106595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China.
    Islam MM; Tan Y; Hameed HMA; Liu Y; Chhotaray C; Cai X; Liu Z; Lu Z; Wang S; Cai X; Su B; Li X; Tan S; Liu J; Zhang T
    J Glob Antimicrob Resist; 2020 Sep; 22():290-295. PubMed ID: 32142951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.
    Juréen P; Angeby K; Sturegård E; Chryssanthou E; Giske CG; Werngren J; Nordvall M; Johansson A; Kahlmeter G; Hoffner S; Schön T
    J Clin Microbiol; 2010 May; 48(5):1853-8. PubMed ID: 20237102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
    Maus CE; Plikaytis BB; Shinnick TM
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3192-7. PubMed ID: 16048924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis.
    Sirgel FA; Tait M; Warren RM; Streicher EM; Böttger EC; van Helden PD; Gey van Pittius NC; Coetzee G; Hoosain EY; Chabula-Nxiweni M; Hayes C; Victor TC; Trollip A
    Microb Drug Resist; 2012 Apr; 18(2):193-7. PubMed ID: 21732736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens.
    Hillemann D; Rüsch-Gerdes S; Richter E
    J Clin Microbiol; 2009 Jun; 47(6):1767-72. PubMed ID: 19386845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis.
    Krüüner A; Jureen P; Levina K; Ghebremichael S; Hoffner S
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2971-3. PubMed ID: 12937004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of MDR-TB Beijing/W and other Mycobacterium tuberculosis genotypes in Nairobi, Kenya.
    Githui WA; Jordaan AM; Juma ES; Kinyanjui P; Karimi FG; Kimwomi J; Meme H; Mumbi P; Streicher EM; Warren R; van Helden PD; Victor TC
    Int J Tuberc Lung Dis; 2004 Mar; 8(3):352-60. PubMed ID: 15139475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic and phenotypic characteristics of aminoglycoside-resistant Mycobacterium tuberculosis isolates in Latvia.
    Bauskenieks M; Pole I; Skenders G; Jansone I; Broka L; Nodieva A; Ozere I; Kalvisa A; Ranka R; Baumanis V
    Diagn Microbiol Infect Dis; 2015 Mar; 81(3):177-82. PubMed ID: 25557624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.